Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
A3
12
Buffer StageUnless otherwise specified 3in the individual monograph3, the requirements are met if the quantities of active ingredient dissolved from the units tested conform to Acceptance Table 4. Continue testing through the three levels unless the results of both stages conform at an earlier level. The value of Q in Acceptance Table 4 is 75% dissolved unless otherwise specified 3in the individual monograph3. The quantity, Q, 3specified in the individual monograph3 is the total amount of active ingredient dissolved in both the Acid and Buffer Stages, expressed as a percentage of the labeled content. The 5%, 15%, and 25% values in Acceptance Table 4 are percentages of the labeled content so that these values and Q are in the same terms.
Acceptance Table 4 Level B1 B2 Number Tested 6 6 Criteria Each unit is not less than Q + 5%. Average of 12 units (B1 + B2) is equal to or greater than Q, and no unit is less than Q 15%. Average of 24 units (B1 + B2 + B3) is equal to or greater than Q, not more than 2 units are less than Q 15%, and no unit is less than Q 25%.
(W1) (W2)
(W3)
(W4)
The test for Content Uniformity is required for all dosage forms not meeting the above conditions for the 3Weight3 Variation test.s1s2S (USP34)
Table 1. Application of Content Uniformity (CU) and Weight Variation (WV) Tests for Dosage Forms Dose & Ratio of Drug Substance 25 mg <25 mg and or 25% <25% WV CU WV CU CU CU WV CU
B3
12
Dosage Form
Tablets
Capsules
CU WV
CU WV
This general chapter is harmonized with the corresponding texts of the European Pharmacopoeia and the Japanese Pharmacopoeia. Portions of the general chapter text that are national USP text, and are not part of the harmonized text, are marked with symbols (33) to specify this fact. 3NOTEIn this chapter, unit and dosage unit are synonymous.3 To ensure the consistency of dosage units, each unit in a batch should have a drug substance content within a narrow range around the label claim. Dosage units are defined as dosage forms containing a single dose or a part of a dose of drug substance in each unit. The uniformity of dosage units specification is not intended to apply to suspensions, emulsions, or gels in unit-dose containers intended for external, cutaneous administration. The term uniformity of dosage unit is defined as the degree of uniformity in the amount of the drug substance among dosage units. Therefore, the requirements of this
WV
Multiple components
WV CU
WV CU
European Pharmacopoeia and Japanese Pharmacopoeia text not accepted by the United States Pharmacopeia: Alternatively, products listed in item (4) above that do not meet the 25 mg/25% threshold limit may be tested for uniformity of dosage units by Mass Variation instead of the Content Uniformity test if the concentration relative standard deviation (RSD) of the drug substance in the final dosage units is not more than 2%, based on process validation data and development data, and if there has been regulatory approval of such a change. The concentration RSD is the RSD of the concentration per dosage unit (w/w or w/v), where concentration per dosage unit equals the assay result per dosage unit divided by the individual dosage unit weight. See the RSD formula in Table 2.3s2S (USP34)
s1 3
Official from December 1, 2011 Copyright (c) 2012 The United States Pharmacopeial Convention. All rights reserved.
Dosage Form Solutions in unit-dose containers 3and into soft capsules3 Others
Type
Subtype
Change to read:
CONTENT UNIFORMITY
Select not fewer than 30 units, and proceed as follows for the dosage form designated. Where different procedures are used for assay of the preparation and for the Content Uniformity test, it may be neces-
Table 2 Variable Definition Mean of individual contents (1, 2, , n), expressed as a percentage of the label claim Individual contents of the units tested, expressed as a percentage of the label claim Sample size (number of units in a sample) Acceptability constant Sample standard deviation Conditions Value
X 1, 2, , n
n k s
2.4 2.0
RSD
Relative standard deviation (the sample standard deviation expressed as a percentage of the mean) Reference value
100s/X
Reference value
M = X (AV = ks) M = 98.5% (AV = 98.5 X + ks) M = 101.5% (AV = X 101.5 + ks) M=X (AV = ks) M = 98.5% (AV = 98.5 X + ks) M = T% (AV = X T + ks) General formula:
Official from December 1, 2011 Copyright (c) 2012 The United States Pharmacopeial Convention. All rights reserved.
Variable L1 L2
Definition Maximum allowed acceptance value Maximum allowed range for deviation of each dosage unit tested from the calculated value of M
Conditions
On the low side, no dosage unit result can be less than [1(0.01)(L2)]M, while on the high side, no dosage unit result can be greater than [1 + (0.01)(L2)]M. (This is based on an L2 value of 25.0.)
Target content per dosage unit at the time of manufacture, expressed as a percentage of the label claim. sUnless otherwise stated, T is 100.0%, or T is the manufacturers approved target content per dosage unit.s2S (USP34)
3
WEIGHT3 VARIATION
Carry out an assay for the drug substance(s) on a representative sample of the batch using an appropriate analytical method. This value is result A, expressed as percentage of label claim (see Calculation of Acceptance Value). Assume that the concentration (weight of drug substance per weight of dosage unit) is uniform. Select not fewer than 30 dosage units, and proceed as follows for the dosage form designated.
Hard Capsules
Accurately weigh 10 capsules individually, taking care to preserve the identity of each capsule. Remove the contents of each capsule by a suitable means. Accurately weigh the emptied shells individually, and calculate for each capsule the net 3weight3 of its contents by subtracting the 3weight3 of the shell from the respective gross 3weight3. Calculate the drug substance content of each capsule from the 3net weight3 of the individual capsule 3content3 and the result of the Assay. Calculate the acceptance value.
Change to read:
Soft Capsules
Accurately weigh 10 intact capsules individually to obtain their gross 3weights3, taking care to preserve the identity of each capsule. Then cut open the capsules by means of a suitable clean, dry cutting instrument such as scissors or a sharp open blade, and remove the contents by washing with a suitable solvent. Allow the occluded solvent to evaporate from the shells at room temperature over a period of about 30 minutes, taking precautions to avoid uptake or loss of moisture. Weigh the individual shells, and calculate the net contents. Calculate the drug substance content in each capsule from the 3weight3 of product removed from the individual capsules and the result of the Assay. Calculate the acceptance value.
CRITERIA
Apply the following criteria, unless otherwise specified.
Official from December 1, 2011 Copyright (c) 2012 The United States Pharmacopeial Convention. All rights reserved.
General Chapters
General Information
Add the following:
Flow cytometry is an analytical method that plays a critical role in the quantitative and qualitative assessment of cell populations in patient and cellular product samples. The power of flow cytometry lies in its ability to rapidly and reliably analyze multiple attributes of individual cells within heterogeneous cell populations. Despite the value of flow cytometry data, method validation is challengingperhaps more so than for other analytical methodsbecause of errors and artifacts from multiple sources. Although flow cytometric methods can also be used to sort and isolate cells as part of the manufacturing process for cell- and tissue-based biological products, the scope of this chapter is limited to the use of flow cytometry as an analytical method. This chapter presents the technical aspects of the method, including instrumentation, sample handling and staining, and data analysis. Sources of error are considered in the context of technical features, as well as in the discussion of quality control, quality assurance, and standardization. Finally, current applications and assay troubleshooting principles are presented. For additional information on the basics and practical aspects of flow cytometry, see the current edition of Practical Flow Cytometry (Shapiro, 2003). Flow cytometry is widely used to characterize cell and tissue-based products, but most assay methods are not yet standardized. In addition to issues related to technical complexity, there are also challenges to standardization of flow cytometric methods for specific product classes or types related to the heterogeneous nature of these products, even among those with similar manufacturing processes and clinical uses. Current and future innovations in instrumentation, analytic reagents, analytic algorithms, and automation are likely to improve the technologys capabilities but are unlikely to eliminate challenges (e.g., bioassay, identification tests, and other applications).
that individual cells can be observed or interrogated for characteristics such as size, granularity, and presence of surface membrane or intracellular antigens or molecules. The cells are suspended in fluid in which movement is controlled by the size and configuration of tubing, chambers, and pumps specific to the flow cytometry instrument. The pattern of light signals produced from the laser lights interaction with the cells is captured by a detection system, also specific to the instrument, and the detected signals are transformed into data elements that can be analyzed and combined with data from other cells in a given sample. Data from a cell suspension can then be expressed and presented in one-, two-, or three-dimensional visual formats, or in numerical formats, to characterize the cellular sample and its subpopulations both qualitatively and quantitatively.
Official from December 1, 2011 Copyright (c) 2012 The United States Pharmacopeial Convention. All rights reserved.